Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (BMC Cancer, (2021), 21, 1, (904), 10.1186/s12885-021-08630-w)

Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George

Research output: Contribution to journalComment/debatepeer-review

Abstract

Following publication of the original article [1], it was noticed that uncorrected page proofs were mistakenly published. The publishers apologise for this error. The original article [1] has been corrected. Below is a table of corrections which have been implemented in the original article. (Table presented.).

Original languageEnglish (US)
Article number1023
JournalBMC cancer
Volume21
Issue number1
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (BMC Cancer, (2021), 21, 1, (904), 10.1186/s12885-021-08630-w)'. Together they form a unique fingerprint.

Cite this